Drug Profile
LY 368975
Latest Information Update: 30 Jul 2002
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Obesity therapies; Propylamines; Small molecules
- Mechanism of Action Adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 15 Jun 1999 Preclinical development for Obesity in USA (PO)